Parallel Advisors LLC grew its holdings in Johnson & Johnson (NYSE:JNJ – Get Rating) by 8.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 51,906 shares of the company’s stock after purchasing an additional 4,139 shares during the quarter. Parallel Advisors LLC’s holdings in Johnson & Johnson were worth $9,322,000 as of its most recent SEC filing.
A number of other institutional investors have also bought and sold shares of the business. BlackRock Inc. lifted its stake in Johnson & Johnson by 2.6% in the 4th quarter. BlackRock Inc. now owns 200,021,352 shares of the company’s stock worth $34,217,654,000 after purchasing an additional 4,982,885 shares in the last quarter. State Street Corp lifted its stake in Johnson & Johnson by 1.8% in the 4th quarter. State Street Corp now owns 144,677,639 shares of the company’s stock worth $24,750,004,000 after purchasing an additional 2,492,359 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Johnson & Johnson by 2.5% during the 4th quarter. Geode Capital Management LLC now owns 44,405,610 shares of the company’s stock worth $7,576,867,000 after buying an additional 1,084,834 shares during the last quarter. Norges Bank acquired a new stake in shares of Johnson & Johnson during the 4th quarter worth approximately $4,172,929,000. Finally, Legal & General Group Plc increased its holdings in shares of Johnson & Johnson by 5.8% during the 4th quarter. Legal & General Group Plc now owns 17,420,146 shares of the company’s stock worth $2,980,062,000 after buying an additional 948,306 shares during the last quarter. 68.78% of the stock is owned by hedge funds and other institutional investors.
Insider Transactions at Johnson & Johnson
In other news, EVP Kathryn E. Wengel sold 40,000 shares of Johnson & Johnson stock in a transaction on Friday, June 10th. The shares were sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the completion of the sale, the executive vice president now directly owns 71,311 shares of the company’s stock, valued at approximately $12,336,803. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other news, EVP Kathryn E. Wengel sold 40,000 shares of Johnson & Johnson stock in a transaction on Friday, June 10th. The shares were sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the completion of the sale, the executive vice president now directly owns 71,311 shares of the company’s stock, valued at approximately $12,336,803. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CAO Robert J. Decker sold 8,462 shares of Johnson & Johnson stock in a transaction on Thursday, May 26th. The stock was sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the sale, the chief accounting officer now directly owns 15,473 shares of the company’s stock, valued at $2,785,140. The disclosure for this sale can be found here. Corporate insiders own 0.35% of the company’s stock.
Wall Street Analyst Weigh In
A number of analysts have recently issued reports on the stock. SVB Leerink cut their price target on shares of Johnson & Johnson from $200.00 to $194.00 in a report on Wednesday. The Goldman Sachs Group raised their price target on shares of Johnson & Johnson from $163.00 to $181.00 and gave the stock a “neutral” rating in a report on Tuesday, April 12th. Raymond James raised their price target on shares of Johnson & Johnson from $195.00 to $196.00 and gave the stock an “outperform” rating in a report on Wednesday, April 20th. Wells Fargo & Company raised their price target on shares of Johnson & Johnson from $190.00 to $195.00 and gave the stock an “overweight” rating in a report on Wednesday, July 13th. Finally, Credit Suisse Group lifted their target price on shares of Johnson & Johnson from $200.00 to $205.00 and gave the company an “outperform” rating in a report on Wednesday, April 20th. Four research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and an average price target of $189.89.
Johnson & Johnson Stock Performance
Shares of JNJ stock opened at $171.31 on Friday. The company has a quick ratio of 1.14, a current ratio of 1.39 and a debt-to-equity ratio of 0.39. Johnson & Johnson has a 52 week low of $155.72 and a 52 week high of $186.69. The stock has a market capitalization of $450.79 billion, a PE ratio of 24.94, a P/E/G ratio of 3.42 and a beta of 0.63. The firm has a 50 day moving average of $176.35 and a two-hundred day moving average of $174.34.
Johnson & Johnson (NYSE:JNJ – Get Rating) last issued its quarterly earnings results on Tuesday, July 19th. The company reported $2.59 EPS for the quarter, beating the consensus estimate of $2.57 by $0.02. Johnson & Johnson had a net margin of 19.21% and a return on equity of 36.56%. The company had revenue of $24.02 billion during the quarter, compared to analysts’ expectations of $23.85 billion. During the same quarter last year, the company posted $2.48 EPS. The firm’s revenue was up 3.0% compared to the same quarter last year. On average, research analysts predict that Johnson & Johnson will post 10.01 EPS for the current fiscal year.
Johnson & Johnson Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 6th. Shareholders of record on Tuesday, August 23rd will be given a $1.13 dividend. The ex-dividend date is Monday, August 22nd. This represents a $4.52 annualized dividend and a yield of 2.64%. Johnson & Johnson’s dividend payout ratio is presently 65.79%.
Johnson & Johnson Profile
(Get Rating)
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.
Recommended Stories
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).
Want More Great Investing Ideas?
Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.
